Two ARPA-H stealth exits in one day. That’s not a coincidence — that’s a signal. Renovare Therapeutics just launched out of Boulder, Colorado, as the commercialization arm for a multi-university consortium that landed up to $33.5 million from ARPA-H’s NITRO program. The mission? Disease-modifying osteoarthritis therapies that actually regenerate cartilage and bone.

Let me be clear about what that means. The current OA playbook is pain management — NSAIDs, injections, and eventually a full joint replacement. There is no FDA-approved disease-modifying osteoarthritis drug (DMOAD) on the market. Zero. For a condition that affects over 32 million Americans. That’s the gap Renovare is walking into.

The academic firepower behind this is serious: University of Colorado Boulder, CU Anschutz Medical Campus, and Colorado State University — three institutions pooling their regenerative medicine expertise with ARPA-H dollars behind them. Renovare sits at the end of that pipeline as the entity responsible for turning academic breakthroughs into IND-enabling studies and first-in-human Phase 1 trials.

They’re not the only ones chasing the DMOAD dream. OrthoTrophix recently completed early enrollment of its Phase 2b trial for TPX-100, an injectable peptide targeting cartilage regeneration. But Renovare’s approach — using gene therapies and biomaterials for minimally invasive structural restoration — is a fundamentally different bet. Less “slow down the damage” and more “rebuild what’s lost.”

The NITRO program funding tells you ARPA-H sees regenerative ortho as a frontier worth betting big on. And launching with a built-in consortium of three universities means Renovare has a research engine most early-stage companies spend years trying to assemble. No named assets yet, but the infrastructure is already there. Watch this space.